UK Finance Firm Fights $1.3M Drug Developer's Suit
By Silvia Martelli (January 4, 2022, 12:15 PM GMT) -- A financial services company is fighting a $1.3 million lawsuit brought by a Swiss drug developer, saying it did not have to pay profits made by the pharmaceutical company under currency exchange contracts because they were allegedly entered into for speculative purposes.
Ebury Partners UK Ltd. said in its defense, filed at the High Court on Dec. 20 and now made public, that Carbogen Amcis AG violated its terms and conditions by entering into some 2020 currency exchange contracts for speculative purposes. This entitled Ebury to not pay Carbogen for the profits made, according to the court document.
Carbogen said in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!